A randomized, placebo-controlled, double-blind, sequential, ascending dose study assessing safety, tolerability, pharmacokinetics and pharmacodynamics of BMS-962212 in healthy Japanese and non-Japanese subjects

Trial Profile

A randomized, placebo-controlled, double-blind, sequential, ascending dose study assessing safety, tolerability, pharmacokinetics and pharmacodynamics of BMS-962212 in healthy Japanese and non-Japanese subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2017

At a glance

  • Drugs BMS 962212 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 08 Apr 2017 New trial record
    • 18 Mar 2017 Results (56) of an exposure- response analysis, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top